Obesity Updates: Cutting-edge therapies that are reshaping the future of obesity treatment.
From muscle-preserving drugs to innovative partnerships and groundbreaking research awards the key updates include:
💥 Ascletis ASC47 shows promise as a muscle-preserving obesity treatment with a half-life of up to forty days in Phase Ib studies.
🏅 Rivus Pharmaceuticals reveals impressive Phase 2a results for HU6, demonstrating significant weight loss and improved cardiac health in obesity-related heart failure.
🤔 Harbour BioMed launches Élancé Therapeutics, focusing on obesity treatments that preserve muscle mass through bispecific antibodies.
🇧🇷 Halia Therapeutics wins the prestigious Novo Nordisk Golden Ticket to advance its promising obesity and inflammation research. 💉 Roche and Zealand Pharma partner to co-develop dual receptor agonists, targeting multiple metabolic pathways for effective weight loss.
💰 Viking Therapeutics secures a $150 million deal to produce its obesity treatment, VK2735, and strengthen its position in the growing market.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates on Obesity
#ObesityResearch #HealthcareInnovation #ObesityTreatment #PharmaceuticalNews #LucidQuest #WeightLossSolutions #ClinicalTrials #HealthcareConsulting